Joanne R Chalmers
A5070207982- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Food Allergy and Anaphylaxis Research
- Delphi Technique in Research
- Contact Dermatitis and Allergies
- Neonatal skin health care
- Health Systems, Economic Evaluations, Quality of Life
- Streptococcal Infections and Treatments
- Autoimmune Bullous Skin Diseases
- Antimicrobial Resistance in Staphylococcus
- Clinical practice guidelines implementation
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- melanin and skin pigmentation
- Skin Protection and Aging
- Bacterial Identification and Susceptibility Testing
- Urticaria and Related Conditions
- Psoriasis: Treatment and Pathogenesis
- Autoimmune and Inflammatory Disorders
- Mobile Health and mHealth Applications
- Ethics in Clinical Research
- Antibiotic Use and Resistance
- Olfactory and Sensory Function Studies
- Atherosclerosis and Cardiovascular Diseases
- Hair Growth and Disorders
University of Nottingham
2015-2024
Misgav Ladach
2022
Universidad de Salamanca
2022
Williams (United States)
2020
Queen's Medical Centre
2007-2019
Research Network (United States)
2019
Oregon Health & Science University
2015-2019
Oregon Clinic
2019
Evidence Based Research (United States)
2019
Nottingham University Hospitals NHS Trust
2015-2019
BackgroundAtopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and increasing prevalence. Because of the significant socioeconomic effect atopic its on quality life families, there have been decades research focused prevention, with limited success. Recent advances cutaneous biology suggest barrier defects might be key initiators possibly allergic sensitization.ObjectiveOur objective was to test whether...
BackgroundSkin barrier dysfunction precedes eczema development. We tested whether daily use of emollient in the first year could prevent high-risk children.MethodsWe did a multicentre, pragmatic, parallel-group, randomised controlled trial 12 hospitals and four primary care sites across UK. Families were approached via antenatal or postnatal services for recruitment term infants (at least 37 weeks' gestation) at high risk developing (ie, one first-degree relative with parent-reported eczema,...
Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether strategy of starting treatment doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over oral corticosteroids.We did pragmatic, multicentre, parallel-group randomised controlled trial adults bullous (three or more blisters at two sites and linear basement membrane IgG C3). Participants were randomly assigned to (200 mg per day) prednisolone (0·5 mg/kg...
Core outcome sets are critically important outcomes that should be measured in clinical trials. Their absence atopic dermatitis is a form of research waste and impedes combining evidence to inform patient care. Here, we articulate the rationale for core review work international Harmonising Outcome Measures Eczema group from its inception Munich, 2010. We describe domain determination (what measured), instrument selection (how domains culminating complete measurement set Tokyo, 2019. Using...
Abstract The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence‐based dermatology. Harmonising Outcome Measures for Eczema ( HOME ) initiative an international multiprofessional group dedicated outcomes research. In June 2011, the conducted consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) determine...
Cellulitis of the leg is a common bacterial infection skin and underlying tissue. We compared prophylactic low-dose penicillin with placebo for prevention recurrent cellulitis.
This is the report from fifth meeting of Harmonising Outcome Measures for Eczema initiative (HOME V). The was held on 12–14 June 2017 in Nantes, France, with 81 participants. main aims were (i) to achieve consensus over definition core domain long‐term control and how measure it (ii) prioritize future areas research measurement quality life (QoL) children. Moderated whole‐group small‐group discussions informed by presentations qualitative studies, systematic reviews validation studies....
This article is a report of the fourth meeting Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim was to achieve consensus over preferred outcome instruments measuring patient‐reported symptoms and quality life HOME core set atopic eczema (AE). Following presentations, which included data from systematic reviews, discussions were mixture whole group small discussions. Small groups allocated priori ensure representation...
Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers) but no validated instruments for the domain have identified.To develop a measurement instrument to capture patient's perspective of that is suitable use clinical trials.Best practice development patient-reported was followed. A mixed-methods approach used refine conceptual framework, generate, select items test distribution...
The Harmonising Outcome Measures for Eczema (HOME) initiative has established a core outcome set of domains atopic eczema (AE) clinical trials. Previous consensus meetings have agreed on preferred instruments clinician-reported signs (Eczema Area and Severity Index, EASI) patient-reported symptoms (Patient-Oriented Measure, POEM). This paper reports decisions from the HOME VII meeting.To complete AE by agreeing quality life (QoL), long-term control itch intensity.A face-to-face meeting was...
Food allergy is thought to develop through transcutaneous sensitization, especially in the presence of skin barrier impairment and inflammation. Regular moisturizer application infant could potentially promote sensitization development food allergy.We tested this hypothesis Enquiring About Tolerance (EAT) study population.The EAT was a population-based randomized clinical trial conducted from January 15, 2008, August 31, 2015, recruited 1303 exclusively breastfed 3-month-old infants their...
BACKGROUND: Eczema is the most common inflammatory skin disease of childhood, characterized by an itchy red rash that usually involves face and folds. There currently no curative treatment for eczema, so reduction eczema incidence through prevention a desirable goal. Potential interventions preventing include exclusive breastfeeding, hydrolysed protein formulas soy when bottle feeding, maternal antigen avoidance, omega oil supplementation, prebiotics probiotics. OBJECTIVES: This overview...
Atopic eczema (AE) is a common skin problem that impairs quality of life and associated with the development other atopic diseases including asthma, food allergy allergic rhinitis. AE treatment significant cost burden for health care providers. The purpose trial to investigate whether daily application emollients first year can prevent developing in high-risk infants (first-degree relative or rhinitis). This protocol pragmatic, two-arm, randomised controlled, multicentre trial. Up 1400 term...
Abstract Background The effectiveness of emollients for preventing atopic dermatitis/eczema is controversial. Barrier Enhancement Eczema Prevention trial evaluated the effects daily during first year life on dermatitis and conditions to age 5 years. Methods 1394 term infants with a family history disease were randomized (1:1) emollient plus standard skin‐care advice (693 group) or alone (701 controls). Long‐term follow‐up at ages 3, 4 years was via parental questionnaires. Main outcomes...